Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two-Year Experience

Multiple Sclerosis Journal – Experimental, Translational and Clinical
doi 10.1177/2055217317725102
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

HDL-cholesterol Elevation Associated With Fingolimod and Dimethyl Fumarate Therapies in Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Dimethyl Fumarate Treatment Alters NK Cell Function in Multiple Sclerosis

European Journal of Immunology
AllergyImmunology
2017English

Dimethyl Fumarate for Relapsingremitting Multiple Sclerosis

Prescriber
Pharmacology
2014English

Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases

Frontiers in Immunology
AllergyImmunology
2016English

Dimethyl Fumarate in the Management of Multiple Sclerosis: Appropriate Patient Selection and Special Considerations

Therapeutics and Clinical Risk Management
2016English

Tumefactive Multiple Sclerosis Lesions Under Fingolimod Treatment

Neurology
Neurology
2012English

Debate on the Treatment of Multiple Sclerosis: Experience From an Intractable Multiple Sclerosis Case With Rebound Syndrome After Fingolimod Cessation

Clinical and Experimental Neuroimmunology
NeuroscienceNeurologyImmunologyMicrobiology
2019English

Nonfatal PML in a Patient With Multiple Sclerosis Treated With Dimethyl Fumarate

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy